Validation of Potential Biomarkers for Pancreas Cancer in Human Saliva

Overview

About this study

The goal of this study is to determine if the biomarkers found to be upregulated in tissue samples are specific to PDAC and can be detected in saliva. Saliva will be collected form PDAC and control subjects for comparison. Additionally, to determine if the biomarkers are specific to PDAC or other KRAS driven cancers, saliva will be collected from patients with breast and lung cancer. The saliva collected from these subjects will be studied for the presence of specific protein biomarkers and used in experiments such as western blots and ELISAs.

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers with an extremely low overall 5-year survival rate. In previous experiments, human formalin fixed paraffin embedded (FFPE) PDAC tissue samples were obtained for laser microdissection of precancerous pancreatic lesions. RNA was isolated from the tissue and sequenced. The RNA-seq data suggested that there were many potential biomarkers for PDAC that could positively impact the clinical setting and early-detection of the disease if validated in patient samples.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Men and women between the ages of 20-90 years old.
Young adults are less likely to have pancreas associated illness. We want to sample these individuals so that we can determine what a healthy expression profile would look like. We also want to obtain samples from older individuals that do not have pancreas associated illnesses so that we can use them as proper controls against samples from older patients with pancreatic cancer. This range encompasses a large portion of the population of potential donors on campus.
PDAC, lung and breast cancer patients.
Volunteers to serve as controls with no previous history of jaundice, disease of the pancreas (pancreatitis, pancreatic cyst, and pancreatic cancer), other cancers in the past 5 years or Sjögren’s syndrome or has undergone radiation to the head or neck area. Appropriate volunteers include patient spouses, employees of Mayo Clinic, and relatives of employees of Mayo Clinic.

Exclusion Criteria:

We will not be seeking out one minority group over the other, nor will we be refusing the inclusion of one minority group over the other.

Eligibility last updated 2/7/232. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Jacksonville, Fla. Mayo Clinic principal investigator Peter Storz, Ph.D.	Closed-enrolling by invitation What is this? (?) "Close" Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.	Contact information: Jillian Eisenhauer (904) 953-6382 Eisenhauer.Jillian@mayo.edu

Mayo Clinic Location

Status

Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Peter Storz, Ph.D.

Closed-enrolling by invitation

Contact information:

Jillian Eisenhauer

(904) 953-6382

Eisenhauer.Jillian@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials